Table 1 General characteristics
From: Comparison of various lipid parameters in association of target organ damage: a cohort study
Overall (n = 1599) | Men (n = 711) | Women (n = 888) | P | |
|---|---|---|---|---|
Characteristics | ||||
Ethnics, n (%), (Han = 1, Others = 0) | 1586 (99.6) | 708 (100.0) | 878 (99.3) | 0.03 |
Body height, cm | 159.9 ± 8.3 | 166.4 ± 6.0 | 154.7 ± 5.8 | < 0.001 |
Body weight, kg | 62.4 ± 10.6 | 67.6 ± 10.2 | 58.3 ± 8.9 | < 0.001 |
Drinker, n (%) | 237 (14.8) | 207 (29.1) | 30 (3.4) | < 0.001 |
Cardiovascular risk factors | ||||
Age, years | 71.4 ± 6.1 | 71.3 ± 6.1 | 71.4 ± 6.1 | 0.95 |
Smoker, n (%) | 366 (22.9) | 351 (49.4) | 15 (1.7) | < 0.001 |
Body mass index, kg/m2 | 23.9 ± 3.5 | 23.9 ± 3.3 | 23.9 ± 3.6 | 0.92 |
Fasting plasma glucose, mmol/L | 5.69 ± 1.70 | 5.72 ± 1.67 | 5.67 ± 1.73 | 0.55 |
Systolic blood pressure, mmHg | 134.3 ± 17.7 | 134.3 ± 16.8 | 134.3 ± 18.4 | 0.95 |
Diastolic blood pressure, mmHg | 78.9 ± 9.1 | 80.0 ± 9.2 | 78.1 ± 9.0 | 0.002 |
Lipids/lipoproteins | ||||
Total cholesterol, mmol/L | 5.22 ± 1.01 | 4.92 ± 0.99 | 5.46 ± 0.96 | < 0.001 |
Triglycerides, mmol/L | 1.61 ± 0.93 | 1.54 ± 0.85 | 1.66 ± 1.00 | 0.007 |
HDL-C, mmol/L | 1.38 ± 0.36 | 1.28 ± 0.33 | 1.46 ± 0.36 | < 0.001 |
LDL-C, mmol/L | 3.20 ± 0.85 | 3.04 ± 0.85 | 3.33 ± 0.83 | < 0.001 |
Non-HDL-C, mmol/L | 3.84 ± 0.98 | 3.65 ± 0.97 | 4.00 ± 0.96 | < 0.001 |
TC/HDL ratio | 3.98 ± 1.08 | 4.05 ± 1.12 | 3.92 ± 1.06 | 0.014 |
TG/HDL ratio | 1.32 ± 1.05 | 1.36 ± 0.98 | 1.30 ± 1.10 | 0.26 |
LDL/HDL ratio | 2.45 ± 0.81 | 2.51 ± 0.85 | 2.39 ± 0.77 | 0.005 |
Asymptomatic target organ damage | ||||
Pulse wave velocity, m/s | 9.42 ± 2.31 | 9.36 ± 2.42 | 9.48 ± 2.21 | 0.32 |
Creatinine clearance rate, % | 92.4 ± 21.7 | 88.3 ± 20.0 | 95.8 ± 22.5 | < 0.001 |
Urinary albumine-creatinine ratio, mg/g | 54.9 ± 181.6 | 51.1 ± 108.3 | 58.0 ± 224.4 | 0.43 |
Diseases & treatment | ||||
Hypertension, n (%) | 843 (52.7) | 385 (54.2) | 458 (51.6) | 0.31 |
Treated hypertension, n (%) | 799 (93.9) | 363 (93.1) | 436 (94.6) | 0.36 |
Cardiovascular disease, n (%) | 549 (34.3) | 231 (32.5) | 318 (35.8) | 0.16 |
Anti-platelet treatment, n (%) | 424 (26.6) | 204 (28.8) | 220 (24.8) | 0.07 |
Lipid lowing therapy, n (%) | 259 (16.2) | 102 (14.4) | 157 (17.7) | 0.08 |
Stroke or TIA, n (%) | 318 (19.9) | 130 (18.3) | 188 (21.2) | 0.15 |
Renal disease, n (%) | 132 (8.3) | 55 (7.8) | 77 (8.7) | 0.52 |
Diabetes, n (%) | 312 (19.5) | 137 (19.3) | 175 (19.7) | 0.99 |
Antidiabetic treatment, n (%) | 262 (16.4) | 115 (16.2) | 147 (16.6) | 0.98 |
Insulin treatment, n (%) | 51 (7.4) | 22 (7.2) | 29 (7.5) | 0.90 |